viewCytoDyn Inc.

FDA accepted CytoDyn’s request and plan to submit BLA on rolling basis

CytoDyn Inc. (OTCQB:CYDY) President and CEO Dr. Nader Pourhassan joined Steve Darling from Proactive Investors Vancouver on Skype to talk about encouraging news that the FDA will allow CytoDyn to submit on a rolling basis its planned Biologics License Application for  Leronlimab. This is a humanized IgG4 mAb that is subcutaneously injected to block HIV-1 from entering and infecting immune cells.

Pourhassan told Proactive how rare this is for a company their size and when the first submissions will be made. 

Quick facts: CytoDyn Inc.

Price: 0.28 USD

Market: OTCQB
Market Cap: $108.71 m

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events


The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of CytoDyn Inc. named herein, including the promotion by the Company of CytoDyn Inc. in any Content on the Site, the Company receives from said...



Full interview: CytoDyn offers update on leronlimab following encouraging...

CytoDyn Inc. (OTCQB:CYDY) CEO Nader Pourhassan and IncellDx Inc CEO Dr Bruce Patterson offer an update on leronlimab's mechanism of action (MOA) in regards to its ongoing cancer trials, specifically in metastatic breast cancer. Dr Patterson says the amazing thing about CCR5 is how it plays...

2 days, 13 hours ago

2 min read